Testing effectiveness (Phase 2)Not Yet RecruitingNCT07487519
What this trial is testing
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
Who this might be right for
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Shanghai Henlius Biotech 180